Paid Clinical Trials for Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Showing all 4 results
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
by
CTG
in
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified,
Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements,
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements,
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified,
Recurrent Diffuse Large B-Cell Lymphoma
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by
CTG
in
Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified,
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified,
Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation,
Recurrent ALK Positive Large B-Cell Lymphoma,
Recurrent B-Cell Non-Hodgkin Lymphoma
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites